# **BioDecoder: A miRNA Bio-interpretable Neural Network Model for**

# Noninvasive Diagnosis of Breast Cancer

Lei Liu<sup>1, #</sup>, Weili Lin<sup>1, #</sup>, Suqi Cao<sup>2</sup>, Liu Yang<sup>2</sup>, Sheng Gao<sup>1</sup>, Na Jiao<sup>2</sup>, Lixin Zhu<sup>3</sup>, Ruixin Zhu<sup>1, \*</sup>, Dingfeng Wu<sup>2, \*</sup>

1. Department of Gastroenterology, The Shanghai Tenth People's Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200072, P. R. China.

2. National Clinical Research Center for Child Health, the Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, P. R. China.

3. Department of Colorectal Surgery, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, P. R. China.

<sup>#</sup>These authors contributed equally: Lei Liu, Suqi Cao, and Liu Yang.

<sup>\*</sup>Corresponding authors:

Ruixin Zhu (rxzhu@tongji.edu.cn)

Department of Gastroenterology, The Shanghai Tenth People's Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200072, P. R. China.

Tel: 86-21-6598-1041

Dingfeng Wu (dfw\_bioinfo@126.com)

National Clinical Research Center for Child Health, the Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, P.R. China. Tel: 86-571-8173-2391

# Email

Lei Liu: leiliu@tongji.edu.cn

Weili Lin: linweili@tongji.edu.cn

Suqi Cao: <u>suqi\_cao@outlook.com</u>

Liu Yang: <u>13676735203@163.com</u>

Sheng Gao: gaos@tongji.edu.cn

Na Jiao: jiaona@zju.edu.cn

Lixin Zhu: zhulx6@mail.sysu.edu.cn

Ruixin Zhu: rxzhu@tongji.edu.cn

Dingfeng Wu: dfw bioinfo@126.com

# 1 Abstract

2 Early diagnosis of breast cancer remains a major clinical challenge. Liquid biopsy has 3 become a powerful tool for cancer diagnosis by the aid of various the state-of-the-art detection technologies and artificial intelligence (AI) methods. Although the 4 5 prediction performance is superior, the clinical application of existing AI models is 6 greatly limited due to their poor interpretability. Here, we designed a miRNA-Gene-7 Module-Pathway-Disease biological decoding path, and developed BioDecoder 8 thereof, a miRNA bio-interpretable neural network model for breast cancer early 9 diagnosis. We demonstrated that BioDecoder could achieve early non-invasive diagnosis of breast cancer with a remarkable performance (AUC = 0.989) and showed 10 strong generalizability in an external cohort (AUC = 0.890). Meanwhile, the 11 biologically interpretable results of BioDecoder revealed that significant changes in 12 13 metabolic pathway and oxidative phosphorylation were the main action pathways of 14 circulating miRNA in breast cancer. Our study indicates that BioDecoder offers the 15 promise of non-invasive early diagnosis of breast cancer and can be generalized to 16 other cancers and corresponding biomarkers.

17

18 Keywords: breast cancer, circulating miRNA, biological interpretability, noninvasive19 diagnosis, liquid biopsy

20

# 21 Introduction

Breast cancer is one of the most common malignancies worldwide. According to the 22 23 data released by GLOBOCAN 2020, female breast cancer has surpassed lung cancer 24 as the most commonly diagnosed cancer with about 2.3 million (11.7%) new cases in 2020, being the leading cause of cancer mortality among women<sup>1</sup>. Published research 25 26 has revealed that the 5-year average survival rate of in situ female breast cancer 27 reaches 99.0%, while those of regional- and distant-stage breast cancer are only 86.0% and 29.0%, respectively<sup>2</sup>. Lokong et al.<sup>3</sup> also reported that delayed diagnosis was an 28 29 important reason for the higher breast cancer mortality in low-income countries. Therefore, early screening and diagnosis are essential to improve the overall survival 30 31 rate of breast cancer. Tissue biopsy is the gold standard for clinical diagnosis of breast cancer; however, as an invasive test it is not suitable for early detection <sup>4</sup>. Currently, 32 33 mammogram screening has been commonly used for early diagnosis of breast cancer but with risks of overdiagnosis and radiation exposure <sup>5-7</sup>. Hence, it is imperative to 34 35 develop an accurate and non-invasive alternative tool for the early detection of breast 36 cancer.

Liquid biopsy has become an important means of clinical early screening of cancer<sup>8</sup>, 9. It can detect and analyze circulating tumor DNA (ctDNA), RNA (i.e., mRNA, miRNA), circulating tumor cells (CTC), and exosomes in plasma, urine, and other body fluids, providing information that is difficult to capture in medical imaging<sup>10, 11</sup>. Compared with tissue biopsy, liquid biopsy is non-invasive and easier to monitor tumor oncogenesis, metastasis and treatment response in real time <sup>12, 13</sup>. Although the

medRxiv preprint doi: https://doi.org/10.1101/2023.01.31.23285308; this version posted April 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

43	diagnosis of breast cancer is challenging due to heterogeneity <sup>14</sup> , circulating
44	carcinoma proteins, circulating tumor cells, ctDNA, circulating miRNA, and other
45	biomarkers have been applied in liquid biopsy research of breast cancer and achieved
46	good predictive performance <sup>15, 16</sup> . Among them, the circulating miRNA plays an
47	important role in tumor pathogenesis as oncogenes or tumor suppressors <sup>12, 17</sup> , making
48	it a promising biomarker for breast cancer diagnosis. In previous research, using
49	machine learning algorithms, a panel of five miRNAs (miR-1246, miR-1307-3p, miR-
50	4634, miR-6861-5p and miR-6875-5p) was demonstrated to detect breast cancer with
51	89.7% accuracy <sup>18</sup> , and another set of seven miRNAs including has-miR-126-5p and
52	has-miR-144-3p showed predictive power for triple-negative breast cancer with an
53	area under the receiver operating characteristic curve (AUC) of 0.814 $^{19}$ .

Artificial intelligence (AI), including traditional machine learning algorithms and 54 55 deep learning architectures, has greatly altered the research paradigm in medical science, and has brought new breakthroughs in precise diagnosis, treatment and 56 prognosis of cancer<sup>20</sup>. Relying on the development of AI, liquid biopsy has become a 57 powerful tool for cancer diagnosis <sup>21</sup>. The inherent black-box nature of most AI 58 models, however, hinders their interpretability and widespread clinical application<sup>22</sup>. 59 To help alleviate this problem, eXplainable AI (XAI)<sup>23</sup> has been introduced. Research 60 have revealed that feature importance, model perturbation, feature association, and 61 prior knowledge, etc., can be utilized to improve the interpretability of AI models <sup>24, 25</sup>. 62 By integrating prior biological knowledge, bio-interpretable models (white-box 63 solution) can be constructed to capture potential causality and uncover the underlying 64

65	biological process of diseases with better model credibility and generalizability,
66	thereby promoting the research of disease mechanisms and the identification of
67	therapeutic targets. For example, a recent study by Elmarakeby et al. <sup>26</sup> have
68	demonstrated the capacity of biological XAI model for revealing novel molecularly
69	altered candidates and predicting the staging of prostate cancer patients. Consequently,
70	development of a breast cancer early diagnostic biological XAI model promises great
71	benefits for further popularizing the clinical application of breast cancer liquid biopsy.
72	This study was undertaken to design a miRNA biological decoding path (miBDP)
73	and develop BioDecoder, a miRNA bio-interpretable neural network model, for breast
74	cancer early screening and diagnosis. Integrating prior biological knowledge and AI
75	technology, BioDecoder dramatically ameliorated its biological interpretation ability
76	under the premise of ensuring prediction performance. The findings drawing from
77	BioDecoder provide new insights into the pathogenesis and treatment of breast cancer.
78	

# 79 **Results**

A set of 4113 serum samples, including 2833 control samples (i.e., 2686 non-cancer samples, 93 prostate disease samples and 54 benign breast disease samples) and 1280 breast cancer samples, and corresponding profiles of 2540 circulating miRNAs were obtained as the discovery cohort (Table S1)<sup>18</sup>. We developed a miRNA biointerpretable neural network model (BioDecoder) to diagnose breast cancer, whose performance was compared with traditional black-box models (i.e., random forest [RF] and fully connected neural network [FCN]). The potential mechanism of miRNA in

breast cancer was then explained through BioDecoder. Finally, the predictive
performance of BioDecoder was validated on an external cohort (11 control samples
and 122 breast cancer samples, Table S2) by transfer learning (Figure 1A).

90

# 91 Differential circulating miRNAs as biomarkers for breast cancer diagnosis

Circulating miRNAs in serum have potential for breast cancer diagnosis <sup>27, 28</sup>, which 92 was confirmed in our discovery cohort (Figure 1B). Seven hundred and ten miRNAs 93 94 with significant differences between breast cancer and control samples were screened 95 out  $(|\log_2 FC| > 1 \text{ and } FDR < 0.05; FC: \text{ fold change})$ , including 704 up-regulated 96 miRNAs and 6 down-regulated miRNAs (Table S3). Among them, has-miR-1246 and 97 has-miR-1307-3p, which were significantly overexpressed in breast cancer patients, 98 have been proven to be potent combined markers for early detection of breast cancer 99 in published studies, with a sensitivity of 97.3%, a specificity of 82.9%, and an accuracy of 89.7% <sup>18, 29</sup>. 100

101 These 710 differential miRNAs were mapped to 11,418 target genes in the 102 miRTarBase database (Table S4). As shown in Figure 1C, the results of Kyoto 103 encyclopedia of genes and genomes (KEGG) pathway enrichment analysis revealed 104 that proteoglycans in cancer, hippo signaling pathway and signaling pathway 105 regulating pluripotency of stem cells, etc. were regulated by differential miRNAs and 106 might participate in the onset and progression of cancer. In particular, these target 107 genes were also significantly enriched in breast cancer pathway (FDR < 0.001; Table 108 S5), which was consistent with the results of gene set enrichment analysis (GSEA)

109 (enrichment score = 0.758, FDR < 0.001; Figure 1D, Table S6).

110

## 111 BioDecoder enabled precise diagnosis of breast cancer

112 By leveraging the prior biological knowledge, a miRNA-Gene-Module-Pathway-113 Disease biological decoding path (miBDP) was extracted from databases to 114 characterize the biological process of miRNAs in the body (Figure 2A). Based upon 115 miBDP, we constructed the miRNA bio-interpretable neural network model 116 (BioDecoder) for breast cancer diagnosis. The 710 differential miRNAs were fed into 117 BioDecoder as input, and then 11,418 targeted genes, 116 modules and 70 pathways 118 from miRTarBase and KEGG were used as hidden layers for information extraction 119 (Table S4), followed by a disease layer that outputs the probability of breast cancer 120 (Figure 2A and Figure S1). For comparison, similar neural network architecture was 121 used in FCN. However, different from FCN, each neuron in BioDecoder represented a 122 specific biological entity, and the links between adjacent layers were partially 123 connected according to the real biological relationship, rather than fully connected 124 (Figure S1). Moreover, in view of the class imbalance issue in the discovery cohort, 125 the synthetic minority oversampling technique (SMOTE) was performed to balance 126 the sample size of the two classes (i.e., control and cancer), thereby improving model 127 stability (Figure 2B, C).

After 100 epochs training, the validation losses were minimized (Figure 2D) and the area under the receiver operating characteristic curves (AUC) was stable at the highest scores (Figure 2E). The results confirmed that RF, FCN and BioDecoder all had

excellent prediction performance (AUC > 0.97; Table 1, Figure 2F and G, and Figure S2). Nevertheless, the validation AUC of RF was significantly higher than its test AUC, suggesting an overfitting problem. BioDecoder showed a comparable performance to FCN although it had more restrictions on model architecture (Table 1). BioDecoder with oversampling achieved the best performance for predicting risk of breast cancer on the test set (AUC = 0.989, balanced accuracy = 0.960, precision = 0.949, recall = 0.943) and was used for subsequent analysis.

138

# BioDecoder revealed the underlying pathological mechanisms of miRNA in breast cancer

BioDecoder is a neural network architecture with bio-entity connections between adjacent layers (i.e., miRNA, gene, module and pathway), which can reflect the specific changes of these bio-entities in breast cancer. Ranking the pathways in BioDecoder by weights, it was found that several pathways, such as metabolic pathway, ribosome, oxidative phosphorylation, and DNA replication, were significantly different between the control and cancer samples (P < 0.001), and were of prime importance to breast cancer early diagnosis (Figure 3A, B).

Specifically, hsa-miR-3659 and hsa-miR-190a-3p had high weights in the metabolic pathway (including 97 modules, 406 genes, and 403 miRNAs, Figure S3A) that has an important influence on breast cancer occurrence <sup>30</sup>. The ribosome pathway is involved in the proliferation and metastasis of breast cancer cells <sup>31-35</sup>, in which hsamiR-17-3p and hsa-miR-3622b-3p were the key factors (Figure S3B). Oxidative

153	phosphorylation contained 10 energy metabolism modules (e.g., F-type ATPase and
154	V-type ATPase), 84 genes, and 81 miRNAs (Figure 3C). A subset of miRNAs
155	targeting these modules also obtained good diagnostic capabilities for breast cancer.
156	For instance, a set of 38 miRNAs (such as hsa-miR-3146 and hsa-miR-330-3p) in the
157	F-type ATPase module achieved excellent diagnostic performance (AUC = $0.953$ ),
158	while the only miRNA (hsa-miR-3664-3p) in the V-type ATPase module yielded an
159	AUC up to 0.868 (Figure 3C). Interestingly, we found that some target genes of
160	miRNAs could affect the prognosis of breast cancer (Figure 3D, E). Low expression
161	of ATP5F1B ( $P < 0.001$ ) and ATP6AP137 ( $P < 0.001$ ) significantly improved the
162	breast cancer prognosis, and the 5-year survival increased from 70% and 77% to 85%,
163	respectively.

164

#### 165 Extended application and validation of BioDecoder

166 The superior biological interpretability of BioDecoder opens up encouraging 167 prospects in its clinical practice. As presented in Figure 4A, besides significantly 168 distinguishing non-cancer and breast cancer samples (P = 2.666e-224), BioDecoder 169 could also accurately identify other diseases, such as prostate disease (P = 2.302e-9) and benign breast disease (P = 1.539e-12). Meanwhile, although patients with benign 170 171 breast disease were highly likely to develop cancer at miRNA level, the probability was still significantly lower than that of breast cancer patients (P = 0.040, Figure 4A). 172 173 It indicated that BioDecoder has the potential for early screening of breast cancer.

BioDecoder contained the biological decoding path of miRNA, and the sample

175	distribution of each level in miBDP is presented in Figure 4B. At the miRNA level,
176	the model could roughly distinguish between control and breast cancer samples;
177	nevertheless, disease samples were chaotic at principal component analysis (PCA)
178	space. As the decoding proceeded, the distinctions between different categories
179	increased gradually. At the module and pathway levels, there were significant
180	differences among breast cancer, prostate disease and non-cancer samples, while
181	benign breast disease samples were close to breast cancer samples (Figure 4B).
182	To evaluate the robustness and generalization ability of BioDecoder, an external
183	validation was performed by transfer learning. The external validation cohort included
184	miRNA expression profiles of breast tissue from 122 breast tumor patients and 11
185	healthy individuals <sup>36</sup> . The first four layers of BioDecoder were frozen, and only the
186	weights of the output layer were updated in transfer learning (Figure 4C). Taking into
187	consideration different sampling proportions (10%-70%) of the external training set,
188	BioDecoder exhibited better generalizability than FCN-BioDecoder achieved an
189	excellent diagnostic performance with only a few external training samples, yielding
190	AUC up to 0.890 (Figure 4D, E).

191

# 192 **Discussion**

Breast cancer is the most common malignant cancer in women and its early diagnosis can effectively reduce mortality <sup>37</sup>. The accuracy of breast cancer early screening has always been the coalface of research <sup>2, 38</sup>. In this study, we designed a miRNA biointerpretable neural network model, BioDecoder, for noninvasive diagnosis of breast

197 cancer. Based upon miRNA expression profile of serum sample, BioDecoder achieved 198 superior predictive performance for breast cancer (area under the receiver operating 199 characteristic curve [AUC] = 0.989). In addition, BioDecoder showed strong 200 robustness and clinical generalizability (AUC = 0.890) through transfer learning, even 201 for breast tissue samples.

202 Liquid biopsy has been commonly used in cancer diagnosis due to its high sensitivity and specificity, especially with the aid of artificial intelligence (AI)<sup>39, 40</sup>. 203 204 Such black-box models, however, could hardly integrate into daily clinical practice owing to their poor bio-interpretability <sup>22</sup>. To alleviate this issue, here we developed 205 206 BioDecoder based on the architecture of miRNA biological decoding path (miBDP, miRNA-Gene-Module-Pathway-Disease) <sup>24, 41</sup>. The bio-interpretable miBDP 207 208 architecture not merely considerably reduces the number of parameters and enhances modeling efficiency (Figure S1)<sup>26</sup>, but also guarantees BioDecoder great benefits in 209 210 digging into the pathogenesis of breast cancer and discovering potential therapeutic 211 targets (Figure 2, 3). The construction of Biodecoder is a decoding process of miRNA 212 expression information according to miBDP, in which different diseases and their stages can be effectively distinguished (Figure 4B). Besides the excellent predictive 213 214 power, BioDecoder exhibited outstanding performance in transfer learning (Figure 215 4D), implying that biologically interpretable architecture has an edge in terms of 216 model generalizability and clinical application.

Clinically, circulating miRNAs has been proved to be related to the pathogenesis
 of breast cancer <sup>28, 42</sup>, and can be used as biomarkers for breast cancer diagnosis, such

219	as has-miR-1246 and has-miR-1307-3p <sup>18, 29</sup> . In our results, 710 differential miRNAs
220	were significantly enriched in breast cancer related pathways. Through the biological
221	interpretation of miBDP, metabolism and oxidative phosphorylation were found to be
222	the key pathways for miRNA to regulate the development of breast cancer, which
223	indicates that metabolism may be reprogrammed in breast cancer <sup>27, 43, 44</sup> . Moreover,
224	under the regulation of miRNAs, some genes, such as ATP5F1B and ATP6AP1, could
225	affect the prognosis of breast cancer. Studies have shown that the increased
226	expression of genes in oxidative phosphorylation pathway plays an major role in the
227	immunotherapeutic drug resistance of breast cancer, which could be reversed by the
228	knockdown or inhibition of ATP synthase <sup>45</sup> . Our findings suggests that BioDecoder's
229	interpretability can offer new thoughts for refining clinical diagnosis and precise
230	treatment of breast cancer.

231 Although BioDecoder uncovered the key pathways for the onset and progression of breast cancer, the mechanism of miRNA targeting these pathways still needs 232 233 experimental verification. In essence, the interpretability of BioDecoder comes from prior biological knowledge, and therefore detailed biological knowledge (e.g., genetic 234 235 information, clinical characteristics, and various molecular experimental data) can improve model performance in capturing the real causality. Also, the transferability 236 and predictive performance of similar architecture applied to other biomarkers and 237 diseases need to be further evaluated. 238

239

# 240 Conclusions

241	Our study proposed a bio-interpretable neural network architecture, namely
242	BioDecoder, which can accurately diagnose breast cancer and reveal the potential
243	mechanism of miRNA in breast cancer. Based on reliable prior knowledge, this bio-
244	interpretable architecture has great potential to be applied to other types of biomarkers
245	and diseases.

246

247 Methods

#### 248 Discovery cohort

The data used in this work can be acquired from the ArrayExpress database 249 (https://www.ebi.ac.uk/biostudies/arrayexpress). The discovery cohort (E-GEOD-250 251 73002, Table S1) consists of 1280 serum samples from breast cancer patients and 252 2833 serum samples from control samples (i.e., 2686 non-cancer samples, 93 prostate disease samples and 54 benign breast disease samples)<sup>18</sup>. Samples from breast cancer 253 254 patients with the following characteristics were excluded: (1) given drugs before 255 serum collection and (2) with concurrent or previously diagnosed advanced cancer in 256 other organs. Serum samples of control samples with no history of cancer or hospitalization within the past 3 months were included for analysis. The miRNA 257 expression profiles of all samples were obtained by microarray analysis and verified 258 259 by quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR).

260

## 261 External validation cohort

262 The external cohort includes 133 Spanish breast tissue samples (i.e., 122 breast cancer

263	samples and 11 control samples, Table S2), which was reported by Matamala et. al.
264	(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58606) <sup>36</sup> . The miRNA
265	expression profiles of all tissue samples were obtained by microarray analysis and
266	verified by quantitative RT-PCR.
267	

# 268 Experimental setup

A stratified random sampling was performed to divide the discovery cohort into two subsets: 60% for training set (768 breast cancer samples and 1700 control samples) and 40% for test set (512 breast cancer samples and 1133 control samples). Then the training set was oversampled to balance the number of positive and negative samples using the synthetic minority oversampling technique (SMOTE) algorithm of the *imblearn* package (version 0.9.1) <sup>46</sup>.

275

# 276 Construction of artificial intelligence (AI) models

## 277 Random Forest (RF) model

The RF model was constructed by the *scikit-learn* (version 0.21.3) package. In the training set, we performed feature selection through recursive feature elimination using cross-validation. Subsequently, a 5-fold cross-validation and grid search were used for model training and hyperparameter tuning. Area under the receiver operating characteristic curve (AUC) was used as the primary evaluation measure for model selection. Finally, the RF model was constructed using the optimal features and hyperparameters (max\_features = 0.1, n\_estimators = 101, max\_depth = None,

285 max\_samples = None, criterion = gini, and class\_weight = balanced).

#### 286 BioDecoder and Fully Connected Neural Network (FCN) models

The neural network models were constructed by the *pytorch* (version 1.13) package  $4^{7}$ . 287 288 The architecture of neural network consisted of one input layer (miRNA), three 289 hidden layers (gene, module and pathway), and one output layer (disease). The input 290 and hidden layers included linear function, rectified linear unit (ReLU) function, 291 batch normalization (BatchNorm1d) function and dropout function, while the output 292 layer contained only linear and BatchNorm1d functions, followed by the softmax 293 function for classification (Figure S1). To make each layer biologically interpretable, 294 we fixed the number of neurons according to the corresponding miRNA, gene, 295 module and pathway, and links between adjacent layers were partially connected 296 through a mask matrix, which was a boolean matrix representing real biological 297 connections between layers, thereby providing biological meaning for the neurons 298 between each layer. Notably, FCN had the same configuration as BioDecoder, except 299 that the layers of FCN were fully connected and were not biologically meaningful 300 (Figure S1).

The model was trained by Adam optimizer <sup>48</sup> (learning rate = 0.01, batch size = 64, and minimal epoch = 100) with batch gradient descent, and used cross entropy as the loss function. To prevent overfitting, the model was early stopped when the validation loss was minimized. The model was then applied to the test set to assess model performance. Evaluation metrics such as balanced accuracy, precision, recall and AUC were reported.

307

#### **308** Assessment of transfer learning robustness

309	Transfer learning <sup>49,50</sup> was used to validate the predictive performance of BioDecoder
310	on an external cohort. The first four layers of the BioDecoder were frozen, while the
311	weights of pathway-disease were retrained by external training set (Figure S1). By the
312	stratified random sampling, the external cohort was divided into two unequal parts-
313	that is, the external training set and external test set. The training set was used to tune
314	the transfer learning model (at the sampling proportion from 10% to 70%), and the
315	test set was used to evaluate the model performance.

316

#### 317 Statistics Analysis

318 All statistical analysis was performed using R software (version 4.2.1) or Python 319 software (version 3.9.6). Statistical significance was assessed using the Wilcoxon 320 signed-rank test, unless otherwise specified. The differentially expressed miRNAs 321 between breast cancer samples and control samples were established using a linear regression model in the R package *limma*  $^{51}$ . The resulting P values were corrected 322 323 using the Benjamini-Hochberg (BH) method. The biomarkers that were differentially expressed miRNAs were screened by false discovery rate (FDR) < 0.05 and fold 324 325 change (FC) > 2, or FDR < 0.05 and FC < 0.5. The corresponding target genes of differential miRNAs were obtained from miRTarBase database <sup>52</sup>, and module and 326 327 pathway information were extracted from the Kyoto encyclopedia of genes and 328 genomes (KEGG). Pathway enrichment analysis was performed using the R packages

329	clusterProfiler <sup>53</sup> and GESA <sup>54</sup> . The PCA method from the python package scikit-learn						
330	was applied for principal component analysis (PCA). Gene expression data for breast						
331	cancer survival analysis were collected from the Human Protein Atlas						
332	(https://www.proteinatlas.org/). The network graph was visualized by Cytoscape						
333	( <u>https://cytoscape.org/</u> , version 3.9.0).						
334							
335	Abbreviations						
336	AI, Artificial Intelligence;						
337	AUC, Area Under the ROC Curve						

- 338 BH, Benjamini-Hochberg;
- 339 CTC, Circulating Tumor Cells;
- 340 ctDNA, circulating tumor DNA;
- 341 ctRNA, circulating tumor RNA;
- 342 GSEA, Gene Set Enrichment Analysis
- 343 FC, Fold Change;
- 344 FCN, Fully Connected Neural Network;
- 345 FDR, False Discovery Rate;
- 346 KEGG, Kyoto Encyclopedia of Genes and Genomes;
- 347 miBDP, miRNA Biological Decoding Path;
- 348 OS, Oversampling;
- 349 RF, random forest;
- 350 ROC, Receiver Operating Characteristic;
- 351 RT-PCR, Reverse Transcription-Polymerase Chain Reaction;
- 352 SMOTE, Synthetic Minority Oversampling Technique;
- 353 XAI, eXplainable Artificial Intelligence;
- 354
- 355 Key Points
- Artificial intelligence technology combines prior biological knowledge greatly

357	improves	the model	interpret	ability v	while ensu	iring the	prediction	performance.

- BioDecoder achieved accurate early diagnosis of breast cancer and showed strong
   robustness and clinical expandability.
- The pathways, such as metabolic, ribosome, oxidative phosphorylation and DNA
   replication, played key roles in the pathogenesis of breast cancer.
- 362

#### 363 Acknowledgements

We are grateful for all the subjects who participated in this study. BioDecoder framework and its biological prior knowledge schematic were created with *BioRender* (https://biorender.com/), and network graph were draw with *cytoscape*.

367

## 368 Authors' contributions

Dingfeng Wu and Ruixin Zhu conceived and designed the project. Each author has contributed significantly to the submitted work. Lei Liu, Suqi Cao and Liu Yang was responsible for the data analysis and drafted the manuscript. Lixin Zhu, Sheng Gao, Weili Lin, Na Jiao, RuixinZhu and Dingfeng Wu revised the manuscript. All authors read and approved the final manuscript.

374

#### 375 Funding

This work was supported by the National Natural Science Foundation of China (32200529 to Dingfeng Wu, 82170542 to Ruixin Zhu, 92251307 to Ruixin Zhu, 82000536 to Na Jiao), and the National Key Research and Development Program of China (2021YFF0703700/2021YFF0703702 to Ruixin Zhu).

380

## 381 Ethics approval and consent to participate

382 N/A

383

#### **384** Consent for publication

385 Obtained.

#### 386

#### 387 Competing interests

- 388 The authors declared no potential conflicts of interest in terms of the research,
- authorship, and/or publication of this article.

390

#### 391 Availability of data and materials

392 No new sequencing data was used in this paper. All the software packages used in this

393 study are open source and publicly available and the code used in this study is

available on GitHub at https://github.com/ddhmed/BioDecoder.

395

#### **Reference**

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
 and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*.
 2021;71(3):209-249. doi:10.3322/caac.21660

400 2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. Jan 2022;72(1):7401 33. doi:10.3322/caac.21708

402 3. Lukong KE, Ogunbolude Y, Kamdem JP. Breast cancer in Africa: prevalence, treatment options,
403 herbal medicines, and socioeconomic determinants. *Breast Cancer Res Treat*. Nov 2017;166(2):351404 365. doi:10.1007/s10549-017-4408-0

405 4. Lowry KP, Bissell MCS, Miglioretti DL, et al. Breast Biopsy Recommendations and Breast Cancers
406 Diagnosed during the COVID-19 Pandemic. *Radiology*. May 2022;303(2):287-294.
407 doi:10.1148/radiol.2021211808

408 5. Ryser MD, Lange J, Inoue LYT, et al. Estimation of Breast Cancer Overdiagnosis in a U.S. Breast
409 Screening Cohort. Ann Intern Med. Apr 2022;175(4):471-478. doi:10.7326/m21-3577

410 6. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for
411 diagnosis, treatment and follow-up<sup>†</sup>. Ann Oncol. Aug 1 2019;30(8):1194-1220.
412 doi:10.1093/annonc/mdz173

413 7. Jatoi I, Pinsky PF. Breast Cancer Screening Trials: Endpoints and Overdiagnosis. J Natl Cancer Inst.
414 Sep 4 2021;113(9):1131-1135. doi:10.1093/jnci/djaa140

415 8. Liu NN, Jiao N, Tan JC, et al. Multi-kingdom microbiota analyses identify bacterial-fungal
416 interactions and biomarkers of colorectal cancer across cohorts. *Nat Microbiol*. Feb 2022;7(2):238-250.
417 doi:10.1038/s41564-021-01030-7

418 9. Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov.

419 Apr 2021;11(4):858-873. doi:10.1158/2159-8290.Cd-20-1311

420 10. Krebs MG, Malapelle U, André F, et al. Practical Considerations for the Use of Circulating Tumor

421 DNA in the Treatment of Patients With Cancer: A Narrative Review. JAMA Oncology. 2022;8(12):1830-

422 1839. doi:10.1001/jamaoncol.2022.4457

423 11. Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: opportunities and
424 challenges. Ann Oncol. Apr 2021;32(4):466-477. doi:10.1016/j.annonc.2021.01.074

425 12. Raza A, Khan AQ, Inchakalody VP, et al. Dynamic liquid biopsy components as predictive and

426 prognostic biomarkers in colorectal cancer. J Exp Clin Cancer Res. Mar 15 2022;41(1):99.
427 doi:10.1186/s13046-022-02318-0

428 13. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J
429 Hematol Oncol. Sep 12 2022;15(1):131. doi:10.1186/s13045-022-01351-y

430 14. Giordano SB, Gradishar W. Breast cancer: updates and advances in 2016. Curr Opin Obstet
431 Gynecol. Feb 2017;29(1):12-17. doi:10.1097/GCO.0000000000343

432 15. Zhou E, Li Y, Wu F, et al. Circulating extracellular vesicles are effective biomarkers for predicting

response to cancer therapy. *EBioMedicine*. May 2021;67:103365. doi:10.1016/j.ebiom.2021.103365

434 16. Luo H, Wei W, Ye Z, Zheng J, Xu RH. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.

435 *Trends Mol Med*. May 2021;27(5):482-500. doi:10.1016/j.molmed.2020.12.011

436 17. Zhang S, Zhou Y, Wang Y, et al. The mechanistic, diagnostic and therapeutic novel nucleic acids for

437 hepatocellular carcinoma emerging in past score years. *Brief Bioinform*. Mar 22 2021;22(2):1860-1883.
438 doi:10.1093/bib/bbaa023

439 18. Shimomura A, Shiino S, Kawauchi J, et al. Novel combination of serum microRNA for detecting
440 breast cancer in the early stage. *Cancer Sci.* Mar 2016;107(3):326-34. doi:10.1111/cas.12880

441 19. Kahraman M, Röske A, Laufer T, et al. MicroRNA in diagnosis and therapy monitoring of early-

442 stage triple-negative breast cancer. *Sci Rep*. Aug 2 2018;8(1):11584. doi:10.1038/s41598-018-29917-2

443 20. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat*444 *Med.* Jan 2019;25(1):44-56. doi:10.1038/s41591-018-0300-7

44521. Cucchiara F, Petrini I, Romei C, et al. Combining liquid biopsy and radiomics for personalized446treatment of lung cancer patients. State of the art and new perspectives. Pharmacol Res. Jul

447 2021;169:105643. doi:10.1016/j.phrs.2021.105643

Talukder A, Barham C, Li X, Hu H. Interpretation of deep learning in genomics and epigenomics. *Brief Bioinform*. May 20 2021;22(3)doi:10.1093/bib/bbaa177

450 23. Gunning D, Aha D. DARPA's Explainable Artificial Intelligence (XAI) Program. *Al Magazine*.
451 2019;40(2):44-58. doi:https://doi.org/10.1609/aimag.v40i2.2850

452 24. Novakovsky G, Dexter N, Libbrecht MW, Wasserman WW, Mostafavi S. Obtaining genetics
453 insights from deep learning via explainable artificial intelligence. *Nat Rev Genet*. Oct 3
454 2022;doi:10.1038/s41576-022-00532-2

455 25. Linardatos P, Papastefanopoulos V, Kotsiantis S. Explainable AI: A Review of Machine Learning
456 Interpretability Methods. *Entropy (Basel)*. Dec 25 2020;23(1)doi:10.3390/e23010018

457 26. Elmarakeby HA, Hwang J, Arafeh R, et al. Biologically informed deep neural network for prostate
458 cancer discovery. *Nature*. 2021;598(7880):348-352. doi:10.1038/s41586-021-03922-4

459 27. Kandettu A, Radhakrishnan R, Chakrabarty S, Sriharikrishnaa S, Kabekkodu SP. The emerging role

of miRNA clusters in breast cancer progression. *Biochim Biophys Acta Rev Cancer*. Dec
2020;1874(2):188413. doi:10.1016/j.bbcan.2020.188413

462 28. Soheilifar MH, Masoudi-Khoram N, Madadi S, et al. Angioregulatory microRNAs in breast cancer:

463 Molecular mechanistic basis and implications for therapeutic strategies. J Adv Res. Mar 2022;37:235-464 253. doi:10.1016/j.jare.2021.06.019 465 29. Zhai LY, Li MX, Pan WL, et al. In Situ Detection of Plasma Exosomal MicroRNA-1246 for Breast 466 Cancer Diagnostics by a Au Nanoflare Probe. ACS Appl Mater Interfaces. Nov 21 2018;10(46):39478-467 39486. doi:10.1021/acsami.8b12725 468 30. Wang T, Fahrmann JF, Lee H, et al. JAK/STAT3-Regulated Fatty Acid  $\beta$ -Oxidation Is Critical for 469 Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab. Jan 9 2018;27(1):136-150.e5. 470 doi:10.1016/j.cmet.2017.11.001 471 31. Ebright RY, Lee S, Wittner BS, et al. Deregulation of ribosomal protein expression and translation 472 promotes breast cancer metastasis. Science. Mar 27 2020;367(6485):1468-1473. 473 doi:10.1126/science.aay0939 474 32. Jin J, Qiu S, Wang P, et al. Cardamonin inhibits breast cancer growth by repressing HIF-1 $\alpha$ -475 dependent metabolic reprogramming. J Exp Clin Cancer Res. Aug 27 2019;38(1):377. 476 doi:10.1186/s13046-019-1351-4 477 33. Chu W, Zhang X, Qi L, et al. The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability 478 and Promotes Growth and Metastasis in Breast Cancer. Cancer Res. Jul 1 2020;80(13):2737-2750. 479 doi:10.1158/0008-5472.Can-19-3326 480 34. Li X, Wang M, Li S, et al. HIF-1-induced mitochondrial ribosome protein L52: a mechanism for 481 breast cancer cellular adaptation and metastatic initiation in response to hypoxia. Theranostics. 482 2021;11(15):7337-7359. doi:10.7150/thno.57804 483 35. Chu W, Zhang X, Qi L, et al. The EZH2–PHACTR2–AS1–Ribosome Axis induces Genomic Instability 484 and Promotes Growth and Metastasis in Breast Cancer. Cancer Research. 2020;80(13):2737-2750. 485 doi:10.1158/0008-5472.can-19-3326 486 36. Matamala N, Vargas MT, González-Cámpora R, et al. Tumor MicroRNA Expression Profiling 487 Identifies Circulating MicroRNAs for Early Breast Cancer Detection. Clinical Chemistry. 488 2015;61(8):1098-1106. doi:10.1373/clinchem.2015.238691 489 37. Mann RM, Hooley R, Barr RG, Moy L. Novel Approaches to Screening for Breast Cancer. Radiology. 490 Nov 2020;297(2):266-285. doi:10.1148/radiol.2020200172 491 38. Alba-Bernal A, Lavado-Valenzuela R, Domínguez-Recio ME, et al. Challenges and achievements of 492 liquid biopsy technologies employed in early breast cancer. EBioMedicine. Dec 2020;62:103100. 493 doi:10.1016/j.ebiom.2020.103100 494 39. Li J, Guan X, Fan Z, et al. Non-Invasive Biomarkers for Early Detection of Breast Cancer. Cancers 495 (Basel). Sep 27 2020;12(10)doi:10.3390/cancers12102767 496 40. Hamam R, Hamam D, Alsaleh KA, et al. Circulating microRNAs in breast cancer: novel diagnostic 497 and prognostic biomarkers. Cell Death Dis. Sep 7 2017;8(9):e3045. doi:10.1038/cddis.2017.440 498 41. Doshi-Velez F, Kim B. Towards A Rigorous Science of Interpretable Machine Learning. 499 2017:arXiv:1702.08608. Accessed February 01, 2017. 500 https://ui.adsabs.harvard.edu/abs/2017arXiv170208608D 501 42. Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, 502 prognosis and therapy prediction. Pharmacol Ther. Apr 2017;172:34-49. 503 doi:10.1016/j.pharmthera.2016.11.012 504 43. Viale A, Pettazzoni P, Lyssiotis CA, et al. Oncogene ablation-resistant pancreatic cancer cells 505 depend on mitochondrial function. Nature. Oct 30 2014;514(7524):628-32. doi:10.1038/nature13611 506 44. Bacci M, Giannoni E, Fearns A, et al. miR-155 Drives Metabolic Reprogramming of ER+ Breast

507	Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase						
508	Inhibitors. <i>Cancer Res</i> . Mar 15 2016;76(6):1615-26. doi:10.1158/0008-5472.Can-15-2038						
509	45. Gale M, Li Y, Cao J, et al. Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to						
510	ATP Synthase Inhibition. Cancer Res. Feb 1 2020;80(3):524-535. doi:10.1158/0008-5472.CAN-18-3985						
511	46. Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: Synthetic Minority over-Sampling						
512	Technique. J Artif Int Res. 2002;16(1):321–357.						
513	47. Paszke A, Gross S, Massa F, et al. PyTorch: An Imperative Style, High-Performance Deep Learning						
514	Library. 2019;						
515	48. Kingma D, Ba J. Adam: A Method for Stochastic Optimization. International Conference on						
516	Learning Representations. 2014;						
517	49. Novakovsky G, Saraswat M, Fornes O, Mostafavi S, Wasserman WW. Biologically relevant transfer						
518	learning improves transcription factor binding prediction. Genome Biology.						
519	2021;22(1)doi:10.1186/s13059-021-02499-5						
520	50. Gao Y, Cui Y. Deep transfer learning for reducing health care disparities arising from biomedical						
521	data inequality. <i>Nat Commun</i> . Oct 12 2020;11(1):5131. doi:10.1038/s41467-020-18918-3						
522	51. Smyth GK. limma: Linear Models for Microarray Data. In: Gentleman R, Carey VJ, Huber W,						
523	Irizarry RA, Dudoit S, eds. Bioinformatics and Computational Biology Solutions Using R and						
524	<i>Bioconductor</i> . Springer New York; 2005:397-420.						
525	52. Huang H-Y, Lin Y-C-D, Li J, et al. miRTarBase 2020: updates to the experimentally validated						
526	microRNA-target interaction database. <i>Nucleic acids research</i> . 2020;48(D1):D148-D154.						
527	doi:10.1093/nar/gkz896						
528	53. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes						
529	among gene clusters. <i>OMICS</i> . 2012;16(5):284-287. doi:10.1089/omi.2011.0118						
530	54. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based						
531	approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. Oct 25						
532	2005;102(43):15545-50. doi:10.1073/pnas.0506580102						
533							

# 534 Table

# 535 Table 1. The predictive performance of random forest, fully connected neural

	Training	Validation		Test			
Model	Loss	Loss	AUC	AUC	Accuracy <sup>*</sup>	Precision	Recall
Raw data							
RF	NA	NA	0.991	0.977	0.980	0.967	0.969
FCN	0.128	0.352	0.990	0.989	0.964	0.960	0.945
BioDecoder	0.889	0.359	0.988	0.986	0.955	0.948	0.934
Oversampled	data						
RF	NA	NA	0.995	0.977	0.979	0.963	0.971
FCN	0.125	0.348	0.989	0.988	0.958	0.951	0.938
BioDecoder	0.246	0.353	0.988	0.989	0.960	0.949	0.943

# 536 network, and BioDecoder.

<sup>\*</sup> Balanced accuracy; RF: random forest; FCN: fully connected neural network; NA: not

538 applicable.

539

540 **Figure Legends** 

Figure 1. Differential changes of circulating miRNAs in breast cancer. (A) The workflow of this study for breast cancer diagnosis based on circulating miRNAs. (B) Principal component analysis (PCA) of miRNA profiles showed different distribution between breast cancer and control samples in the discovery cohort. (C) The top 25 KEGG pathways enriched by the target genes of differential miRNAs. (D) Gene set enrichment analysis results of differential miRNA target genes in breast cancer for pathways.

Figure 2. The architecture and performance of BioDecoder. (A) BioDecoder 548 549 framework. This figure was created with BioRender.com (https://biorender.com/). (B) 550 The distribution of control samples and breast cancer samples in the discovery cohort. 551 (C) The distribution of control samples and breast cancer samples in the discovery 552 cohort after oversampling. (D) The validation loss calculated by cross\_entropy 553 function during model training. (E) The AUC scores obtained during model training. 554 (F) AUC of BioDecoder-OS on the test set. (G) Confusion matrix of BioDecoder-OS 555 on the test set. SMOTE: synthetic minority oversampling technique; FCN: fully 556 connected neural network; OS: oversampling; AUC: area under the receiver operating 557 characteristic curve.

Figure 3. Biological interpretation of BioDecoder. (A) The pathway importance
ranked by weights. (B) Boxplot of differential expression between control and breast

560	cancer samples for the four important pathways (metabolic pathway, ribosome,
561	oxidative phosphorylation, and DNA expression). (C) The biological network of
562	oxidative phosphorylation pathway. Logistic regression was performed using
563	miRNAs in each module and the receiver operating characteristic curves (ROC) were
564	showed. (D). Survival curves of breast cancer patients based on ATP5F1B expression.
565	Survival curves of breast cancer patients based on ATP6AP1 expression. *** , $P <$
566	0.001.

567 Figure 4. Application and validation of BioDecoder. (A) The probability of breast 568 cancer predicted by BioDecoder in non-cancer, prostate disease, benign breast disease and breast cancer samples. The differences between groups were shown. (B) The 569 570 distribution of test set samples at different miRNA biological decoding path levels of 571 BioDecoder. (C) The flow chart of transfer learning for applying BioDecoder on the 572 external cohort. (D) The transfer learning performance of BioDecoder and fully 573 connected neural network on external cohort with different sampling proportions of 574 the training set. (E) The receiver operating characteristic curve of BioDecoder's 575 transfer learning performance on the full external cohort. OS: oversampling.

576

#### 577 Supplementary material

Figure S1. The neural network architecture of fully connected neural network,BioDecoder and transfer learning.

Figure S2. The receiver operating characteristic curve and confusion matrix of random forest, fully connected neural network and Biodecoder in raw data and oversampling data.

583 Figure S3. The biological network of metabolic pathway and ribosome pathway.

- Table S1. Discovery cohort (E-GEOD-73002).
- Table S2. The external validation cohort (GSE58606).
- Table S3. The 710 miRNAs with significant differences between breast cancer and
- 587 control samples.
- Table S4. The correspondence of biological entries in miBDP.
- Table S5. Pathway enrichment of miRNA targeted genes by clusterProfiler.
- 590 Table S6. Pathway enrichment of miRNA targeted genes by GSEA.
- 591







